NAS:EIDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:EIDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.
Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.
For the Biotechnology subindustry, Eidos Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Short Interest distribution charts can be found below:
* The bar in red indicates where Eidos Therapeutics's Short Interest falls into.
Uma Sinha | director, officer: Chief Scientific Officer | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101 |
Franco Valle | officer: Senior Vice President, Finance | 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070 |
Cameron Turtle | officer: Chief Business Officer | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104 |
Jonathan C Fox | officer: See Remarks | C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Suzanne Sawochka Hooper | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Douglas Rohlen | director | 3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447 |
Eric Aguiar | director | 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Rajeev M. Shah | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ali J. Satvat | director, 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025 |
William Lis | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Christine Siu | officer: CFO and Secretary | C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101 |
Bridgebio Pharma, Inc. | 10 percent owner | 421 KIPLING STREET PALO ALTO CA 94301 |
Neil Kumar | director, 10 percent owner, officer: Chief Executive Officer | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
Hoyoung Huh | director | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Peter Kolchinsky | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By Business Wire Business Wire • 10-07-2020
By PRNewswire PRNewswire • 10-06-2020
By PRNewswire PRNewswire • 10-23-2020
By Marketwired Marketwired • 11-08-2020
By Business Wire Business Wire • 10-08-2020
By PRNewswire PRNewswire • 12-05-2020
By PRNewswire PRNewswire • 10-16-2020
By PRNewswire PRNewswire • 10-06-2020
By Marketwired Marketwired • 01-04-2021
By Marketwired Marketwired • 10-09-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.